Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials
出版年份 2021 全文链接
标题
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials
作者
关键词
-
出版物
LANCET INFECTIOUS DISEASES
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2021-12-08
DOI
10.1016/s1473-3099(21)00681-2
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- B cell memory: Understanding COVID-19
- (2021) Isaak Quast et al. IMMUNITY
- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
- (2021) Jennifer M. Dan et al. SCIENCE
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2021) Zhiwei Wu et al. LANCET INFECTIOUS DISEASES
- Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization
- (2021) Guo-Lin Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
- (2021) Nicole Doria-Rose et al. NEW ENGLAND JOURNAL OF MEDICINE
- Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination
- (2021) Rishi R. Goel et al. Science Immunology
- SARS-CoV-2-specific T cell immunity to structural proteins in inactivated COVID-19 vaccine recipients
- (2021) Yao Deng et al. Cellular & Molecular Immunology
- Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis
- (2021) Xinhua Chen et al. CLINICAL INFECTIOUS DISEASES
- Considerations in boosting COVID-19 vaccine immune responses
- (2021) Philip R Krause et al. LANCET
- Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
- (2021) Alberto M Borobia et al. LANCET
- Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
- (2021) Amy Flaxman et al. LANCET
- Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
- (2021) Joana Barros-Martins et al. NATURE MEDICINE
- Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
- (2021) Angela Choi et al. NATURE MEDICINE
- Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
- (2021) Jamie Lopez Bernal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
- (2021) Alejandro Jara et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
- (2021) Ann R. Falsey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
- (2021) Yinon M. Bar-On et al. NEW ENGLAND JOURNAL OF MEDICINE
- New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021
- (2021) Eli S. Rosenberg et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021
- (2021) Srinivas Nanduri et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021
- (2021) Mark W. Tenforde et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
- (2021) Sara Y Tartof et al. LANCET
- CoronaVac induces lower neutralising activity against variants of concern than natural infection
- (2021) Vimvara Vacharathit et al. LANCET INFECTIOUS DISEASES
- Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
- (2020) Alicia T. Widge et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2020) Yanjun Zhang et al. LANCET INFECTIOUS DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search